Jump to main content
Jump to site search

Issue 52, 2016, Issue in Progress
Previous Article Next Article

Targeted delivery of vincristine to T-cell acute lymphoblastic leukemia cells using an aptamer-modified albumin conjugate

Author affiliations

Abstract

Clinical application of vincristine in treatment of cancer is restricted because of its poor solubility and neuropathy. Targeted delivery of cytotoxic drugs could improve their therapeutic efficacy and reduce their severe side effects. Biocompatibility and high accumulation of human serum albumin nanoparticles (HSA) in tumors make this substance an ideal candidate for biomedical usage. Here, a Vincristine–HSA–Sgc8c aptamer (Apt) complex was designed and assessed for the treatment of Molt-4 cells (human acute lymphoblastic leukemia T-cell, target). Vincristine–HSA conjugate and Vincristine–HSA–Apt complex formations were analyzed by particle size analyzer, transmission electron microscopy (TEM) and gel retardation assay. Internalization of the Vincristine–HSA–FAM (3′-fluorescein)-labeled Apt complex into Molt-4 (target) and U266 cells (B lymphocyte human myeloma, nontarget) was monitored by confocal imaging and flow cytometry analysis. For cell viability (MTT assay), both cell lines were treated with vincristine, Vincristine–HSA conjugate, HSA–Apt conjugate and Vincristine–HSA–Apt complex. Vincristine was efficiently loaded (8.5%) into HSA. The results of confocal imaging and flow cytometry analysis indicated that the Vincristine–HSA–FAM-labeled Apt complex was effectively internalized into target cells (Molt-4) but not into nontarget cells (U266). The results of MTT assay also confirmed the internalization data. The Vincristine–HSA–Apt complex had less cytotoxicity in U266 cells compared to vincristine alone and Vincristine–HSA conjugate. In conclusion, the developed drug delivery system acquired properties of high drug loading, high cancer cell accumulation and cancer cell targeting.

Graphical abstract: Targeted delivery of vincristine to T-cell acute lymphoblastic leukemia cells using an aptamer-modified albumin conjugate

Back to tab navigation

Article information


Submitted
02 Apr 2016
Accepted
04 May 2016
First published
06 May 2016

RSC Adv., 2016,6, 46366-46371
Article type
Paper

Targeted delivery of vincristine to T-cell acute lymphoblastic leukemia cells using an aptamer-modified albumin conjugate

S. M. Taghdisi, N. M. Danesh, M. Ramezani and K. Abnous, RSC Adv., 2016, 6, 46366 DOI: 10.1039/C6RA08481H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.


Social activity

Search articles by author

Spotlight

Advertisements